At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 6, 2026 at 08:03 ET
ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materials for its drug ANKTIVA, confirming a cited television ad was never aired and removing a podcast under review. The company is implementing enhanced compliance measures, including executive training and external oversight.
- FDA issued a Warning Letter on March 13, 2026, concerning promotional materials for ANKTIVA.
- ImmunityBio confirmed the cited television advertisement was never broadcast or disseminated.
- The company removed the identified podcast from its website and requested removal from third-party platforms.
- Corrective actions include mandatory executive training, expanded Promotional Review Committee (PRC) protocols, and engagement of external regulatory counsel.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access